Telix CEO, Dr Christian Behrenbruch recently facilitated an international expert panel discussion at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Mid-Winter Symposium entitled: “Ga-68 PSMA-11: Advances in Technology, Demand & Supply”.
The session highlighted state-of-the-art PSMA-PET imaging in men with prostate cancer and how the radiopharmaceutical industry can meet the rapidly increasing demand for this new imaging modality. Industry leaders share insights on topics such as isotope production, distribution and supply chain, as well as the practical impact for physicians.